Evogene (NASDAQ: EVGN, TASE: EVGN) is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture.[1]
Technology and partnerships
Evogene has developed computational biology platforms leveraging big data and artificial intelligence (AI), including machine learning algorithms.
In June 2007, Haaretz reported that Evogene announced a collaboration with SunGene of Germany to develop plant biotechnology-engineering techniques. The project was supported by the Israel-Germany BioDisc program, the Israeli Ministry of Science and Technology